Objective: To examine the outcomes of a Medicare population who participated in a program (provided by Omaha Health) combining digital health with human coaching for diabetes risk reduction.
Method: People at risk for diabetes enrolled in a program combining digital health with human coaching. Participation and health outcomes were examined at 16 weeks and 6 and 12 months.
Results: A total of 501 participants enrolled; 92% completed at least nine of 16 core lessons. Participants averaged 19 of 31 possible opportunities for weekly program engagement. At 12 months, participants lost 7.5% (SD = 7.8%) of initial body weight; among participants with clinical data, glucose control improved (glycosylated hemoglobin [HbA1c] change = −0.14%, p = .001) and total cholesterol decreased (−7.08 mg/dL, p = .008). Self-reported well-being, depression, and self-care improved (p < .0001).
Discussion: This Medicare population demonstrated sustained program engagement and improved weight, health, and well-being. The findings support digital programs with human coaching for reducing chronic disease risk among older adults.
Read More: http://journals.sagepub.com/doi/full/10.1177/0898264316688791?utm_source=Rock+Weekly&utm_campaign=a1b05706ab-Rock_Weekly_2-13&utm_medium=email&utm_term=0_e44ef774d4-a1b05706ab-90918221&mc_cid=a1b05706ab&mc_eid=79bb3b005e&
Outcomes of a Digital Health Program With Human Coaching for Diabetes Risk Reduction in a Medicare Population
Silk Road Medical Announces Updated Clinical Data on TCAR Presented at the 44th Annual VEITH Symposium
Via: Yahoo! Finance
SUNNYVALE, Calif., Dec. 12, 2016 /PRNewswire/ -- Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announced that the 44th annual VEITH Symposium held November 15-19, 2016, in New York City featured several presentations on the company's ENROUTE® Transcarotid Neuroprotection and Stent System, the first and only products specifically designed and indicated for TransCarotid Artery Revascularization (TCAR). Highlights include 1-year data on the pivotal cohort from ROADSTER 1 and the first interim analysis of the 30-day data from the ROADSTER 2 Post Approval Study.
Via: Business Wire
Former Head of Novartis’ Pharmaceuticals Division to help guide future of company focused on groundbreaking therapy for CNS-related edema
OncoMed Presents Initial First-in-Human Data for Anti-DLL4/VEGF Bispecific and Anti-RSPO3 at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Partial Responses and Stable Disease Achieved with Bispecific as a Single-Agent
REDWOOD CITY, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented initial first-in-human data from its ongoing Phase 1 clinical trials of anti-DLL4/VEGF bispecific (OMP-305B83) and anti-RSPO3 (OMP-131R10) antibodies in two posters at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium being held in Munich, Germany.
Via: The Mercury News
To most, it’s Silicon Valley: the region that produced silicon chip innovators and manufacturers, globally influential high-tech corporations and thousands upon thousands of startup companies.
Via: Oliver Wyman Health
Here, Sean Duffy speaks with Kate Warnock of GuideWell during the Oliver Wyman Health Innovation Summit 2016 and shares how Omada Health's digital innovation and value-based model is impacting people with chronic disease.
Via: PR Newswire
Innovative Minimally Invasive Approach for Neurological Conditions Has Been Used in 1,000 Patient Procedures
Study shows seniors at risk for diabetes and heart disease lose weight, reduce healthcare costs with Omada's program
The digital behavioral health coaching program from Omada Health has been shown to reduce overweight and obese seniors' risk of developing type 2 diabetes and heart disease by helping them lose weight and adopt healthier behaviors, according to a new study.
Peer-Reviewed Study Demonstrates Omada Program Helps Seniors Reduce Risk of Type 2 Diabetes and Heart Disease
Via: Omada Health
Company’s fifth peer-reviewed publication shows seniors engage with the Omada Program and lose weight; model estimates savings in less than two years
OncoMed Presents Interim Phase 1b Data for Ipafricept and Vantictumab in Pancreatic Cancer at the ESMO 2016 Congress
COPENHAGEN, Denmark and REDWOOD CITY, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) today announced the presentation of interim clinical data from its ongoing Phase 1b trials of ipafricept (FZD8-Fc, OMP-54F28) and vantictumab (anti-Fzd, OMP-18R5) at the European Society of Medical Oncology (ESMO) 2016 Congress.